The role of external beam radiotherapy in the treatment of hepatocellular cancer

Hepatocellular carcinoma (HCC) is increasing in incidence and mortality. Although the prognosis remains poor, long‐term survival has improved from 3% in 1970 to an 18% 5‐year survival rate today. This is likely because of the introduction of well tolerated, oral antiviral therapies for hepatitis C. Curative options for patients with HCC are often limited by underlying liver dysfunction/cirrhosis and medical comorbidities. Less than one‐third of patients are candidates for surgery, which is the current gold standard for cure. Nonsurgical treatments include embolotherapies, percutaneous ablation, and ablative radiation. Technological advances in radiation delivery in the past several decades now allow for safe and effective ablative doses to the liver. Conformal techniques allow for both dose escalation to target volumes and normal tissue sparing. Multiple retrospective and prospective studies have demonstrated that hypofractionated image‐guided radiation therapy, used as monotherapy or in combination with other liver‐directed therapies, can provide excellent local control that is cost effective. Therefore, as the HCC treatment paradigm continues to evolve, ablative radiation treatment has moved from a palliative treatment to both a “bridge to transplant” and a definitive treatment. Hepatocellular carcinoma is increasing in incidence and mortality. Hypofractionated image‐guided radiation therapy can provide excellent local control with acceptable toxicities, shifting radiation from a palliative modality to both a “bridge to transplant” and a definitive treatment option.